Fig. 7: Nano-reshaper inhibited tumor growth and prolonged the survival of mice bearing intracranial GL261 GBM.

a Orthotopic tumor implantation and treatment scheme for ApoE-CaCP, ApoE-pLIGHT@CaP and Nano-reshaper therapy. b Representative in vivo bioluminescence imaging of mice bearing intracranial GL261-luc GBM after treatment with ApoE-CaCP, ApoE-pLIGHT@CaP, or Nano-reshaper on days 6, 10, and 15 post tumor inoculation. c Semi-quantitative results of tumor burden by bioluminescence intensity shown in b (n = 5 mice). d Kaplan–Meier survival curve of intracranial GL261 GBM-bearing mice after various treatment (n = 6 mice). e Changes in the body weight of mice bearing intracranial GL261 GBM during the therapeutic period (n = 6 mice). f Scheme for CD4⁺ or CD8⁺ T-cell depletion and FTY720 administration. Mice were i.p. injected with αCD4 (10 mg/kg), αCD8 (10 mg/kg) or FTY720 (1.5 mg/kg) on days 5, 7, 9, 11, and 13 post tumor inoculation. g Representative in vivo bioluminescence imaging of mice bearing intracranial GL261-luc GBM after depletion of CD4⁺ or CD8⁺ T-cell for Nano-reshaper treatment. h Semi-quantitative results of tumor burden by bioluminescence intensity shown in g (n = 5 mice). i Kaplan–Meier survival curve of intracranial GL261 GBM-bearing mice in CD4⁺ or CD8⁺ T-cell depletion study (n = 6 mice). j Representative in vivo bioluminescence imaging of mice bearing intracranial GL261-luc GBM after reducing peripheral T cells by FTY720 for Nano-reshaper treatment. k Semi-quantitative results of tumor burden by bioluminescence intensity shown in j (n = 5 mice). l Kaplan–Meier survival curve of intracranial GL261 GBM-bearing mice in FTY720 administration study (n = 6 mice). Data were shown as mean ± SD. Error bars represent SD. Significant differences were evaluated in c, h, k using one-way ANOVA with Tukey multiple comparisons post-test, in d, i, l using Kaplan–Meier analysis with log-rank test. Source data are provided as a Source Data file.